Olmesartan Medoxomil/Hydrochlorothiazide Msn Laboratories Europe (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil/hydrochlorothiazide is indicated for hypertension management, acting on the renin‑angiotensin‑aldosterone system and fluid balance.

• Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with edema: combines vasodilation with diuresis to control fluid overload.
• Hypertension in patients requiring a thiazide diuretic: provides added blood‑pressure reduction when monotherapy is insufficient.
• Hypertension in elderly patients: offers effective blood‑pressure control with a once‑daily regimen.
• Hypertension with concomitant metabolic syndrome: assists in managing blood pressure alongside metabolic risk factors.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combination yields additive blood‑pressure reduction through vasodilation and decreased plasma volume.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Severe electrolyte imbalance
• Pancreatitis

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium and sodium levels regularly.
• Pregnancy: avoid use; teratogenic risk is possible.
• Concomitant drugs: review for interactions with potassium‑sparing agents or NSAIDs.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes; careful review is required.

Major Interactions (Avoid)

• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• Aliskiren (in diabetics): increased risk of renal dysfunction.
• Lithium: may increase lithium serum concentrations.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: additive risk of hypotension and renal impairment.
• Antidiabetic agents: may enhance hypoglycaemic effect.
• Antimicroboral agents (e.g., trimethoprim): can affect potassium balance.